Organon & Co. will license exclusive global development, manufacturing and commercial rights to ebopiprant (OBE-022) from Obseva SA. Ebopiprant is a prostaglandin F2α receptor antagonist being developed for treating preterm labor by reducing inflammation and uterine contractions. Obseva could receive tiered double-digit royalties on commercial sales and as much as $500 million in up-front and milestone payments, including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million in sales-based milestones.